Abstract
Terapeutic possbilities in mCRC in 3rd and higher line of treatment are constantly expanding not only by new combinations of actual treatment possibilities, but also by discoveries of new small targeted molecules. Results of clinical studies prove that by right therapeutic intervention, we can prolong lives of highly pre-treated patients without worsening their quality of life.
Ever evolving clinical oncology require us to have constant knowledge of actual therapeutic regimes and formation of new approach in higher lines of treatment in advanced illness.